The short version of tuftsin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
The metabolism of thiotepa primarily takes place in the liver, following both phase 1 and phase 2 metabolic pathways. Phase 1 involves reactions which change chemical moieties such as oxidation, reduction, and hydrolysis, while phase 2 includes the addition of endogenous groups to foreign compounds. Phase 1 metabolism of thiotepa is predominantly mediated by the cytochrome P450 enzyme system, major CYP2B6 and minor CYP3A4. In this phase an oxidation and desulfuration reactions convert thiotepa into its more active metabolite tepa. Tepa itself exhibits a longer plasma half-life (3 to 24 hours) than thiotepa (1 to 3 hours) and contributes to the overall pharmacological activity of the drug. In phase 2 thiotepa is detoxified via the conjugation with glutathione by glutathione S-transferase. This is followed by the removal of the glutamyl and glycine moieties, and concludes with the N-acetylation of the cysteine conjugate by N-acetylase to form thiotepa-mercapturate. This derivative is more water-soluble, facilitating urinary excretion. Tepa is not conjugated to glutathione but reacts further in the urine and plasma to monochloro tepa. The conversion to a β-chloroethyl moiety depends on the pH and the chloride concentration. The formation of monochloride tepa mainly occurs in the urine. Enzymes responsible for metabolising compounds can show varying efficiency in different individuals or populations, this is called polymorphism. In a study regarding thiotepa metabolism by Ekhart et al., it was found that glutathione S-transferase shows polymorphism.
== See also == Joint All-Domain Command and Control – U.S. defense initiative to connect armed forces sensors into a unified network Particle-beam weapon Other nations Mission Sudarshan Chakra – Proposed multi-layer defense system for India Steel Dome – Turkish national air defence system
==== Methylation ==== Methylation of rRNA upholds structural rigidity by blocking base pair stacking and surrounds the 2'-OH group to block hydrolysis. It occurs at specific parts of eukaryotic rRNA. The template for methylation consists of 10-21 nucleotides. 2'-O-methylation of the ribose sugar is one of the most common rRNA modifications. Methylation is primarily introduced by small nucleolar RNA's, referred to as snoRNPs. There are two classes of snoRNPs that target methylation sites, and they are referred to box C/D and box H/ACA. One type of methylation, 2′-O-methylation, contributes to helical stabilization.
In 2005, Sean Kinney came up with the idea of doing a benefit concert for the victims of the tsunami disaster that struck South Asia in 2004. Kinney made calls to his former bandmates, as well as friends in the music community, such as former Alice in Chains manager Susan Silver. Kinney was surprised by the enthusiastic response to his idea. On February 18, 2005, Jerry Cantrell, Mike Inez, and Sean Kinney reunited to perform for the first time in nine years at K-Rock Tsunami Continued Care Relief Concert in Seattle. The band featured Damageplan vocalist Pat Lachman, as well as other special guests including Maynard James Keenan of Tool, Wes Scantlin of Puddle of Mudd and Ann Wilson of Heart. A few months after that experience, the band called Susan Silver and Cantrell's manager Bill Siddons and said they wanted to tour as Alice in Chains again. Alice in Chains was approached by the producers of the CBS reality show Rock Star about being featured on its second season, but the band turned the offer down. In the show, aspiring singers competed to become the lead vocalist of a featured group. On March 10, 2006, the surviving members performed at VH1's Decades Rock Live! concert, honoring fellow Seattle musicians Ann and Nancy Wilson of Heart. They played "Would?" with vocalist Phil Anselmo of Pantera and Down and bass player Duff McKagan of Guns N' Roses and Velvet Revolver, and at the end of the performance Cantrell dedicated the show to Layne Staley and the late Pantera and Damageplan guitarist Dimebag Darrell.
Sources: en.wikipedia.org
SLA SLA printing is a method in which a laser is shined upon a photoreactive liquid material to harden or polymerize. Instead of material being pushed through a nozzle or jet, material sits in a large basin and is slowly hardened. Due to its use of light to harden the material, SLA printers can offer a very high resolution at a lower speed when compared to other methods. This method is often used for protein scaffolding and providing structural support for other printed biological materials. Examples of bioinks used in SLA printers include fibrin, collagen, and some alginates.
Otamahan (おたまはん), developed by Yoshida Furusato Mura (a third-sector company) in Unnan, Shimane (launched 2002). Tamago ni kakeru oshōyu (たまごにかけるお醤油, Soy Sauce for Pouring on Egg), by Teraoka Yuki Jōzō in Fukuyama, Hiroshima. Tamago kake gohan ni kakeru shōyu (玉子かけご飯にかける醤油, Soy Sauce for Pouring on Tamago Kake Gohan), by Hamada Shōyu in Kumamoto. Higeta Tamago kake gohan ni dōzo! (ヒゲタ たまごかけご飯にどうぞ!, Higeta - Please Use for Tamago Kake Gohan!), by Higeta Shōyu in Choshi, Chiba. Tamago ni kakeru dashi shōyu (たまごにかけるだし醤油, Dashi Soy Sauce for Pouring on Egg), by Igagoe Co., Ltd. in Iga, Mie. Kaketarō (かけたろう), by Jinushi Kyōwa Shōkai / Kokekokkō Republic in Taki, Mie. Additionally, specialized furikake seasonings specifically for TKG are also available. Bull-Dog Sauce produced a seasoning mix called Ouchi de Gyūdon-fū Tamago Kake Gohan (おうちで 牛丼風 たまごかけご飯, Gyūdon-Style Tamago Kake Gohan at Home).
=== Natural cancers === Some cancer studies with non-rodent animals have been performed with the unmodified Sendai virus. Thus, after intratumoral injections of the virus, complete or partial remission of mast cell tumors (mastocytomas) was observed in dogs affected by this disease. Short-term remission after an intravenous injection of SeV was described in a patient with acute leukemia treated in the Clinical Research Center of University Hospitals of Cleveland (US) by multiple viruses in 1964. It is also reported that the Moscow strain of SeV was tested by V. Senin and his team as an anticancer agent in a few dozen patients affected by various malignancies with metastatic growth in Russia in the 1990s. The virus was injected intradermally or intratumorally and it caused fever in less than half of the treated patients, which usually disappeared within 24 hours. Occasionally, the virus administration caused inflammation of the primary tumor and metastases. Clinical outcomes were variable. A small proportion of treated patients experienced pronounced long-term remission with the disappearance of primary tumors and metastases. Sometimes the remission lasted 5–10 years or more after virotherapy. Brief descriptions of the medical records of the patients that experiences long-term remission are presented in the patent. Intratumoral injection of UV irradiated and inactivated SeV resulted in an antitumor effect in a few melanoma patients with stage IIIC or IV progressive disease with skin or lymph metastasis.
Sources: en.wikipedia.org
==== Joint replacement ==== If the impact of symptoms of osteoarthritis on quality of life is significant and more conservative management is ineffective, joint replacement surgery may be used. Evidence supports joint replacement for both knees and hips as it is both clinically effective and cost-effective. People who underwent total knee replacement had improved quality of life, were feeling better compared to those who did not have surgery, and may have short- and long-term benefits for quality of life in terms of pain and function. The risk of death within the first 90 days after hip and knee replacements is less than 1%. The risk of serious complications (such as prosthetic joint infections which may require removal of the artificial joint, blood clots, joint dislocations) is less than 5% after hip or knee replacements. 90% of people with a hip replacement and 80% of those with a knee replacement reported little or no arthritis related pain after the procedure. Less than 10% of artificial knees and less than 20% of artificial hips required replacements over 20 years after the initial surgery. Arthroscopic debridement of the knee, also known as "joint resurfacing", is not recommended for the treatment of knee osteoarthritis and has a limited role in people who have osteoarthritis with a meniscal tear who have failed other treatments.
American Brugmansia and Datura Society, Inc. (ABADS) is designated in the 2004 edition of the International Code of Nomenclature for Cultivated Plants as the official International Cultivar Registration Authority for Datura. This role was delegated to ABADS by the International Society for Horticultural Science in 2002.
== Science and medicine == Pathologic complete response (pCR), in neoadjuvant therapy Polymerase chain reaction COVID-19 testing, often performed using the polymerase chain reaction method Phosphocreatine, a phosphorylated creatine molecule Principal component regression, a statistical technique Protein/creatinine ratio, in urine
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.